Drug Trial Radar · NCT01600755
Autologous Cell Therapy for Treatment of Fecal Incontinence
Last checked: Nov 19, 2026Latest source record: Feb 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
53
Actual
Start
Mar 28, 2013
Primary completion
Oct 27, 2021
Study completion Oct 27, 2021
Sponsor
- Lead sponsor
- Cook MyoSiteIndustry
- Sponsor type
- Industry
- First posted
- May 17, 2012
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this clinical study is to investigate the safety and feasibility of Autologous Muscle Derived Cells (AMDC, generic name iltamiocel, preparation of a patient's own cells) injection into the anal sphincter for treatment of patients with fecal incontinence.
Conditions
- Fecal Incontinence
Interventions
IltamiocelBiological
Single intrasphincteric injection of iltamiocel at a dose of 250 x 10\^6 cells
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Treatment-Related Adverse EventsTime frame: 12 months
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
St. Paul's Hospital
Vancouver, British Columbia, Canada
Royal London Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.